Resveratrol for preventing medication-related osteonecrosis of the jaws in rats
dc.contributor.author | Vitale, Marcelo | |
dc.contributor.author | Corrêa, Mônica Grazieli | |
dc.contributor.author | Ervolino, Edilson [UNESP] | |
dc.contributor.author | Cirano, Fabiano Ribeiro | |
dc.contributor.author | Ribeiro, Fernanda Vieira | |
dc.contributor.author | Monteiro, Mabelle Freitas | |
dc.contributor.author | Casati, Marcio Zaffalon | |
dc.contributor.author | Pimentel, Suzana Peres | |
dc.contributor.institution | Paulista University | |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | |
dc.date.accessioned | 2023-07-29T13:46:57Z | |
dc.date.available | 2023-07-29T13:46:57Z | |
dc.date.issued | 2023-01-01 | |
dc.description.abstract | This study evaluated the effect of resveratrol (RES) on the prevention of medication-related osteonecrosis of the jaws (MRONJ) in ovariectomized (OVX) rats treated with zoledronate (ZOL). Fifty rats were distributed in five groups: SHAM (n = 10): non-ovariectomy + placebo; OVX (n = 10):ovariectomy + placebo; OVX + RES (n = 10):ovariectomy + resveratrol; OVX + ZOL (n = 10):ovariectomy + placebo + zoledronate; and OVX + RES + ZOL (n = 10):ovariectomy + resveratrol + zoledronate. The mandibles left sides were analyzed with micro-CT, histomorphometry, and immunohistochemistry. On the right side, bone markers gene expression was analyzed by qPCR. ZOL increased the percentage of necrotic bone and reduced the neo-formed bone compared to groups not receiving ZOL (p < 0.05). RES impacted the tissue healing pattern in OVX + ZOL + RES, reduced inflammatory cell infiltrate, and improved bone formation in the extraction site. Osteoblasts, alkaline phosphatase (ALP)-, and osteocalcin (OCN)-immunoreactive cells were lower in OVX-ZOL than in SHAM, OVX, and OVX-RES. The OXV-ZOL-RES had fewer osteoblasts and ALP- and OCN-cells than the SHAM and OVX-RES. The tartrate-resistant acid phosphatase (TRAP)-positive cells were reduced in the presence of ZOL (p < 0.05), while the TRAP mRNA levels increased with ZOL treatment, with or without resveratrol, compared with the other groups (p < 0.05). RES alone increased superoxide dismutase levels compared to OVX + ZOL and OVX + ZOL + RES (p < 0.05). In conclusion, resveratrol reduced the tissue impairment severity induced by ZOL; however, it could not prevent the occurrence of MRONJ. | en |
dc.description.affiliation | Dental Research Division School of Dentistry Paulista University | |
dc.description.affiliation | Department of Basic Sciences Dental School of Araçatuba University Estadual Paulista UNESP | |
dc.description.affiliationUnesp | Department of Basic Sciences Dental School of Araçatuba University Estadual Paulista UNESP | |
dc.identifier | http://dx.doi.org/10.1111/odi.14544 | |
dc.identifier.citation | Oral Diseases. | |
dc.identifier.doi | 10.1111/odi.14544 | |
dc.identifier.issn | 1601-0825 | |
dc.identifier.issn | 1354-523X | |
dc.identifier.scopus | 2-s2.0-85150598738 | |
dc.identifier.uri | http://hdl.handle.net/11449/248545 | |
dc.language.iso | eng | |
dc.relation.ispartof | Oral Diseases | |
dc.source | Scopus | |
dc.subject | bisphosphonates | |
dc.subject | osteonecrosis | |
dc.subject | osteoporosis | |
dc.subject | ovariectomy | |
dc.subject | resveratrol | |
dc.subject | zoledronic acid | |
dc.title | Resveratrol for preventing medication-related osteonecrosis of the jaws in rats | en |
dc.type | Artigo | |
unesp.author.orcid | 0000-0001-9333-4349[6] | |
unesp.author.orcid | 0000-0001-9234-0536[7] |